Boston Scientific released its 2023 Performance Report highlighting the company’s actions to improve patient outcomes while prioritizing environmental, social and governance (ESG) progress.
“Because we know that patient health is interconnected with the health of communities and of the planet, we take seriously our responsibility to make sustainable progress,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “This dedication is shared by our more than 48,000 employees worldwide, whose talent and commitment to the highest standards of quality allow us to raise the bar, year after year.”
The report describes how teams across the company applied the science and transformation that define Boston Scientific’s business to advance its ESG priorities and goals, focused on advancing innovative care, empowering people and contributing to a healthier planet, while performing with integrity.
Highlights of Boston Scientific’s 2023 ESG progress include:
Helping improve the lives of more than 37 million patients around the world with nearly 90 product launches and $1.4 billion invested in research and development.[1]Advancing health and addressing inequities by increasing diversity in clinical trials, donating more than $76 million to fund global medical research, fellowships, education and charitable organizations.Increasing workforce diversity, with mid-level leadership[2] roles now held by 43.5% of women globally and 22.6% by multicultural employees in the U.S., including Puerto Rico.Achieving 82% renewable electricity,[3] bringing the company closer to meeting its goal of 100% by the end of 2024.Further defining the company’s path to net-zero greenhouse gas emissions by 2050.[4]Delivering more than 40 million products and spending approximately $340 million on small and diverse suppliers.
The Boston Scientific 2023 Performance Report was prepared with reference to the Global Reporting Initiative (GRI) Standards as well as alignment with the Sustainability Accounting Standards Board (SASB) standards for the Medical Equipment & Supplies industry and the Task Force on Climate-related Financial Disclosures (TCFD) recommendations.
Detailed information about the company’s progress is available on its corporate responsibility website.
All data as of December 31, 2023, unless otherwise specified.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
Contact
Media: Emily Anderson +1 617.515.2000
Investors: Jon Monson +1 508.683.5450
[1] Represents GAAP R&D expense per Annual Report on Form 10-K.
[2] Mid-level leadership includes managers, principals, senior managers and fellows.
[3] Includes renewable electricity generated onsite and purchased electricity matched with electricity from renewable sources. Inclusive of all manufacturing and key distribution sites only.
[4] Across the company’s entire value chain (scopes 1, 2 and 3) with a base year of 2019 as approved in 2022 by the Science Based Targets initiative (SBTi) Net-Zero Standard.
